Table 1.
Study, patients, disease, treatment and follow up characteristics of the reviewed articles
|
Patients
characteristics |
Disease and treatment
characteristics |
Follow-up characteristics | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Authors/ Years | Age group | Sex (no.) | Age (range) |
Patients’ disease phase on IM (no.)¥ | Treatment before IM therapy (no.) | Duration of IM therapy (range) month |
IM brand | Initial dose∞ | Treatment modification (no.) | Causes of treatment modification | Response after treatment modification | Follow up (months) |
| Bahoush Gr, et al./2009 (20) | Children | F (8) M (6) |
Median 9.5 (2.5-14) |
CP (14) | NAa | Median 22.5 (2-30) |
Glivec | 300 | two pts discontinued therapy | progression of the disease in one pt and adverse event in the other | Grade 3 or 4 neutropenia and thrombocytopenia noted in two pts on high-dose therapy/improved condition after discontinuation of therapy for two weeks | Median 16.5 Mean 22.5 (2-30 ) |
| Hamidieh AA, et al./2013 (40) | Children | F (13) M (6) |
Median 9.5 (2-16) |
CP (19) | INF (9) HU (12) |
Unlimitedb | NA | 260 | IM dose escalation to 320 (12%) | -No CHR after 3 months or no MCyR after 12 months and at least if the pts relapsed within 3 months after attaining CHR | NA | Median 24 (14.4-100.8) |
| Navidi GR, et al./2005 (17) |
Adult | NA | NA | NA (17) | NA | NA | Gleevec | NA | NA | NA | NA | NA |
| Razmkhah F, et al./2010 (31) | Adult | F (14) M (16) |
Mean 47 (14-83) |
CP (30) | IM 1st line | Mean 28.8 (7-66) | Imatib | 200, 300, 400 |
NA | NAc | NA | NA |
| Valizadeh N /2011 (25) | Adult | M (1) | 28 | NA (1) | IM 1st line | 12 | NA | 400 | NA | NA | NA | NA |
| Jalaeikhoo H, et al./2011 (37) | Adult | F (197) M (220) |
Mean± SD 40.9 ± 14.5 |
CP (417) | HU (NA) | NA | Indian brand | 400 | IM dose escalation to 600 (NA) | -Pts failed to achieve CHR within 3 months | NA | 72 |
| Moshfeghi K, et al./2013 (19) | Adult | F (34) M (52) |
Mean 60 |
CP (86) | NA | NA | Iranian & Indian brand | 400 | IM dose escalation to 800 (NA) | -Absence of appropriate treatment response | NA | 6 |
| Mozaheb Z, et al./2014 (26) | Adult | F (34) M (26) |
Median 48 (13-80) |
CP (49) AP (7) BP (2) |
HU ± INF (13) IM 1st line (47) |
NA | Generic imatinib | 400 | - IM dose escalation to 600-800 mg (10) IM dose reduction to 100-300 mg (5) - IM interruption (9) |
- Inadequate efficacy or intolerability - unresponsiveness or severe toxicity |
After a median follow-up of 36 months from dose escalation, 70% of them remained alive |
Median 44 (8-115) |
| Golabchifar AA,et al./2014 (21) | Adult | F (25) M (36) |
Median 32 Mean± SD 35.5 ± 11.9 (17–67) |
CP (61) | IM 1st line | (12-36) | NA | NA | NA | NA | NA | NA |
| Mohajeri E, et al./2015 (22) | Adult | F (17) M (19) |
Median 44 Mean± SD 43 ± 10 (19-63) |
CP (36) | NA | NA | Imatib & Imatinib-Osveh | 400 | NA | NA | NA | NA |
| Salamizand H, et al./2015 (27) | Adult | F (29) M (41) |
Mean± SD 47.9 ± 13.2 |
CP (59) AP (11) |
IM 1st line | Mean± SD 44.16 ± 23.16 |
Gleevec | 400 | IM dose escalation to 600 mg (14) | -Suboptimal response and failure to IM | NA | NA |
| Payandeh M, et al./2015 (39) | Adult | F (27) M (27) |
Mean± SD 45.7 ± 13.8 (23-78) |
CP (54) | IM 1st line | 6 | Indian brand | 400 | NA | NA | NA | NA |
| Payandeh M, et al./2015 (41) | Adult | F (42) M (43) |
Mean ±SD 47.5 ± 14.5 (23-82) |
CP (85) | IM 1st line | NA | NA | 400 | NA | NA | NA | NA |
| Rejali L, et al./2015 (30) |
Adult | F (14) M (25) |
Mean 46 (22-70) |
CP (NA) AP (NA) BP (NA)d |
NA | 0 to > 61 | NA | 400 | -IM dose Escalation to 500 or 600 mg -Nilotinib or Dasatinib |
-IM resistance | -Failure MR (25; 63.2) -Warning category (4; 10.2) -Optimal response (10; 26.3)Ᵽ |
NA |
| Rostami G, et al./2015 (38) | Adult | F (15) M (15) |
Median 50 (32-70) |
CP (30) | NA | Median 22 Mean± SD 24.9±11.06 (8 to 50) |
NA | 400 | -IM dose Escalation to 600-800 mg (13) -Nilotinib (9) . |
-Suboptimal response | -MMR (10;45.45) -No MMR (12;54.54) -Dead, two of three mutated ptsⱣ |
Median 23 (11-50) |
| Abbasian S, et al./2015 (42) | Adult | F (20) M (28) |
Mean 40 (15-46) |
CP (48) | NA | 24 to 96 | NA | NA | NA | NA | NA | NA |
| Chahardouli B, et al./2013 (23) | Adult | F (23) M (37) |
Mean 44 (12-77) |
CP (43) AP (4) BP (13) |
IFN ± HU (25) IM 1st line (35) |
NA | NA | NA | - IM dose escalation to 600-800 mg and then replacement with Nilotinib and Dasatinib (1) - Dasatinib and BMT (1) |
-Absence of treatment response -Disease development to blastic phase |
- Increased BCR/ABL copy numbers to %86.6 and peak of T315I mutation to 60% and finally death (1) - Relapse 3 months after HSCT and death (1) |
NA |
| Chahardouli B, et al./2013 (24) | Adult | F (43) M (67) |
Median 42 (10-83) |
CP (93) AP (4) BP (13) |
IFN ± HU (25) IM 1st line (85) |
≥ 6 | NA | NA | -IM dose escalation to 600- 800 mg | -Suboptimal response | NA | NA |
| Solali S, et al./2013 (29) | NA | NA | NA | CP (16) AP (10) BP (4) |
NA | NA | NA | NA | NA | NA | NA | NA |
| Nekoohesh L, et al./2019 (36) | Adult | F (119) M (136) |
Median 41.3 (18-84) |
CP (255) | IM 1st line | NA | NA | 400 | NA | NA | NA | Median 34.8 (3-845) |
| Payandeh M, et al./2018 (35) | Adult | F (36) M (24) |
Median 41 (21-80) |
CP (60) | NA | Median 4 (1-10) | NA | 400 | NA | NA | NA | NA |
| Safaei A, et al./2018 (28) | Adults and pediatrics | male:female ratio of 1.8:1). | Mean 44 (4-90) |
CP (81.3%) AP (8.2%) BP (10.4%) |
NA | NA | NA | NA | NA | NA | NA | NA |
| Vatanmakanian M, et al./2019 (32) | Adult | F (11) M (9) |
Median 49 (21-75) |
CP (9) AP (5) BP (6) |
NA | NA | NA | 200-400 for CP300-800 for AP600-800 for BP | NA | NA | NA | 11 |
| Rostami G, et al./2017 (33) | Adult | F (28) M (32) |
Median 49 (17-81) |
CP (60) | NA | Median 48 (3-142) |
NA | 400 or 800 | NA | NA | NA | Median 49 (4-216) |
| Chahardouli B, et al./2019 (18) | Adult | F (38%) M (62%) |
21-82 | NA | NA | 18-60 | NA | NA | NA | NA | NA | NA |
a
Patients excluded if they had received treatment with HU, INF- or cytarabine and any other investigational agent within seven, 14 and 28 days, respectively before starting the study treatment.
b
It means that the patient should take the drug until the disease progressed or relapsed.
c
The dosage of Imatib was adjusted according to non-hematological and hematological toxicities.
d
A lot of information is missed. pt(s): patient(s).
¥
total numbers of patient equal to all patients on imatinib therapy,
∞
imatinib dosing for adult mg/day and for children mg/m2/day,
Ᵽ
Number of patients/all included patients*100 ⱡ Number of patients/number of mutated patients*100, NA; not available or not applicable, IM; imatinib mesylate, HSCT; Hematopoietic stem cell transplantation, CML; chronic myeloid leukemia, CP; chronic phase, AP; accelerated phase, BP; blastic phase, HU; hydroxyurea, INF; interferon, CHR; complete hematologic response, MCyR; Major cytogenetic response, MR; molecular response, MMR; major molecular response